D P Nurse, H Li, D Cenin, S Patel, D Dima, J Edwards, S Farlow, A Bragg, A Mehdi, R Hanna, S J Rotz, D Jagadeesh, A T Gerds, R M Dean, B Pohlman, B K Hamilton, C Brunstein, M Kalaycio, C S Sauter, R M Sobecks
{"title":"Influence of pre-transplant estimated glomerular filtration rate (eGFR) on clinical outcomes after allogeneic hematopoietic cell transplantation.","authors":"D P Nurse, H Li, D Cenin, S Patel, D Dima, J Edwards, S Farlow, A Bragg, A Mehdi, R Hanna, S J Rotz, D Jagadeesh, A T Gerds, R M Dean, B Pohlman, B K Hamilton, C Brunstein, M Kalaycio, C S Sauter, R M Sobecks","doi":"10.1038/s41409-025-02556-8","DOIUrl":null,"url":null,"abstract":"<p><p>Pretransplant renal dysfunction has historically been associated with increased non-relapse mortality (NRM) and inferior overall survival. Novel approaches in conditioning and GVHD prophylaxis have reduced the toxicity of transplant over time, however, the impact of pre-transplant eGFR in the contemporary era is unknown. The aim of this study was to identify a pre-transplant eGFR value associated with increased transplant-related mortality. This retrospective study was performed using data from 724 adult patients who underwent first allogeneic hematopoietic cell transplant (alloHCT) from January 2012 through December 2021. The optimal pre-transplant eGFR value for risk of NRM was identified using Cox-restricted cubic spline plot analysis. Those with an eGFR <70 ml/min had the highest risk for NRM (p < 0.0001). Multivariate analysis confirmed that the risk of NRM remained significantly higher for eGFR <70 ml/min compared to the other higher eGFR categories, while there were no significant differences between the higher eGFR categories. Pre-transplant renal dysfunction is associated with poor outcomes after alloHCT and remains an important criterion when considering patients for transplant. Efforts to preserve renal function prior to transplant by limiting nephrotoxic exposures may have implications for optimizing outcomes after transplant, particularly in patients with other comorbidities.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Marrow Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41409-025-02556-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Pretransplant renal dysfunction has historically been associated with increased non-relapse mortality (NRM) and inferior overall survival. Novel approaches in conditioning and GVHD prophylaxis have reduced the toxicity of transplant over time, however, the impact of pre-transplant eGFR in the contemporary era is unknown. The aim of this study was to identify a pre-transplant eGFR value associated with increased transplant-related mortality. This retrospective study was performed using data from 724 adult patients who underwent first allogeneic hematopoietic cell transplant (alloHCT) from January 2012 through December 2021. The optimal pre-transplant eGFR value for risk of NRM was identified using Cox-restricted cubic spline plot analysis. Those with an eGFR <70 ml/min had the highest risk for NRM (p < 0.0001). Multivariate analysis confirmed that the risk of NRM remained significantly higher for eGFR <70 ml/min compared to the other higher eGFR categories, while there were no significant differences between the higher eGFR categories. Pre-transplant renal dysfunction is associated with poor outcomes after alloHCT and remains an important criterion when considering patients for transplant. Efforts to preserve renal function prior to transplant by limiting nephrotoxic exposures may have implications for optimizing outcomes after transplant, particularly in patients with other comorbidities.
期刊介绍:
Bone Marrow Transplantation publishes high quality, peer reviewed original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation.
The broad scope of the journal thus encompasses topics such as stem cell biology, e.g., kinetics and cytokine control, transplantation immunology e.g., HLA and matching techniques, translational research, and clinical results of specific transplant protocols. Bone Marrow Transplantation publishes 24 issues a year.